focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 22.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (4.545%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 22.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Offer to Shareholders

4 Mar 2015 07:00

RNS Number : 4613G
Angle PLC
04 March 2015
 



For immediate release

 4 March 2015

 

 

ANGLE plc

("ANGLE" or "the Company")

 

OFFER TO SHAREHOLDERS TO RAISE UP TO £1.5 MILLION

 

On 16 February 2015, ANGLE plc (AIM: AGL and OTCQX: ANPCY), the specialist medtech company, announced an issue of equity to raise £7.3 million (before expenses) by way of a Placing and Subscription. In conjunction with the Placing and Subscription, the Board also announced details of an Offer to Qualifying Participants to raise up to an additional £1.5 million (before expenses) through the issue of up to 2,307,692 New Ordinary Shares at an Issue Price of 65 pence per Ordinary Share.

 

The Company is pleased to announce that the Offer, which closed at 11.00 a.m. on 2 March 2015, was more than four times oversubscribed. The Offer raised the Offer Maximum of £1.5 million and, accordingly, 2,307,692 New Ordinary Shares have been issued. It is expected that Qualifying Participants that applied for the Offer will each receive approximately 21.75% of their applications.

 

Application has been made for 2,307,692 New Ordinary Shares to be admitted to trading on AIM. It is expected that admission to AIM will become effective on 10 March 2015.

 

Further details of the Placing, Subscription and Offer were set out in the announcement published by the Company on 16 February 2015.

 

Unless otherwise defined, capitalised terms shall have the same meaning as defined in the circular posted to Shareholders on 16 February 2015 (the "Circular"), which is available to view on the Company's website at www.angleplc.com.

 

 

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"We are delighted to have received such a strong level of support from our retail shareholders with the Offer more than four times over-subscribed. In total we have raised £8.2 million net of expenses in our Placing, Subscription and Offer, which puts ANGLE in a strong position to progress its first clinical application in ovarian cancer."

 

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Dr Christopher Golden (Nominated adviser)

Russell Kerr, Oliver Baxendale (Sales)  

 

020 7397 8900

Buchanan

Mark Court, Sophie Cowles, Jane Glover

020 7466 5000

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEJJMJTMBTMTJA
Date   Source Headline
21st Oct 20226:15 pmRNSIssue of Equity
18th Oct 20227:00 amRNSStreamlining of operations to increase cash runway
17th Oct 20222:23 pmRNSTR-1: Notification of major holdings
12th Oct 20227:00 amRNSFirst regional distribution agreement
30th Sep 20225:30 pmRNSIssue of Equity
30th Sep 20225:30 pmRNSHolding(s) in Company
29th Sep 20227:00 amRNSInterim Results
29th Sep 20227:00 amRNSPositive headline results from ovarian study
28th Sep 20227:00 amRNSStudy using Parsortix in head and neck cancer
13th Sep 20227:00 amRNSNew poster presented at ASCP Meeting
12th Sep 20227:30 amRNSNovel assay predicts malignancy in pelvic mass
1st Sep 20227:00 amRNSNotice of Interim Results and Webcast
28th Jul 20227:00 amRNSNovel insight into metastasis in NSCLC patients
20th Jul 20222:33 pmRNSHolding(s) in Company
20th Jul 20227:00 amRNSNEW STUDY OF PARSORTIX SYSTEM IN NSCLC
19th Jul 202210:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSResults of Capital Raise
14th Jul 20225:24 pmRNSRetail Offer via PrimaryBid
14th Jul 20225:23 pmRNSProposed Placing and Retail Offer
8th Jul 20225:30 pmRNSIssue of Equity
29th Jun 20224:35 pmRNSResult of 2022 Annual General Meeting
27th Jun 20227:00 amRNSSpread of breast cancer accelerates during sleep
23rd Jun 20226:24 pmRNSIssue of Equity
22nd Jun 20227:00 amRNSSecured contract from pharma services customer
16th Jun 20227:00 amRNSPredicting immunotherapy response in SCLC
14th Jun 20227:00 amRNSPotential role of invasive cellular protrusions
30th May 20227:00 amRNSPartnership with major United States urology group
27th May 20227:00 amRNSMolecular characterisation of CTCs
25th May 20224:35 pmRNSPrice Monitoring Extension
25th May 202212:30 pmRNSANGLE receives FDA clearance for Parsortix
20th May 20227:00 amRNSProstate Cancer UK funds new study using Parsortix
28th Apr 20227:00 amRNSPreliminary Results
20th Apr 20227:00 amRNSNotice of Preliminary Results and Webcast
14th Apr 20227:00 amRNSPoster on Parsortix system presented at AACR 2022
1st Apr 20227:00 amRNSIdentifying drug targets in cancer metastasis
29th Mar 20227:00 amRNSRapid information on patient response to therapies
25th Mar 20227:00 amRNSIdentifying therapeutic targets in TNBC patients
15th Mar 20227:00 amRNSUpdate on laboratory accreditation
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20226:29 pmRNSHolding(s) in Company
18th Feb 20225:13 pmRNSIssue of Equity
21st Jan 20227:00 amRNSPotential in immunotherapy treatment selection
17th Jan 20227:00 amRNSConcordance of Parsortix with tissue biopsy
13th Jan 20227:00 amRNSUpdate on lab accreditation and ovarian study
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.